Manuscripts and Publications

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
R
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
Buhr RG, Barjaktarevic IZ, P Quibrera M, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN et al..  2022.  Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.. Am J Respir Crit Care Med. 206(5):554-562.
Baugh A, Buhr RG, Quibrera P, Barjaktarevic I, R Barr G, Bowler R, Han MKing, Kaufman JD, Koch AL, Krishnan J et al..  2022.  Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity.. Sleep. 45(8)
Strand M, Austin E, Moll M, Pratte KA, Regan EA, Hayden LP, Bhatt SP, Boriek AM, Casaburi R, Silverman EK et al..  2020.  A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.. Chronic Obstr Pulm Dis. 7(4):346-361.
Pan Y, Wang D, Chaudhary MFA, Shao W, Gerard SE, Durumeric OC, Bhatt SP, R Barr G, Hoffman EA, Reinhardt JM et al..  2022.  Robust Measures of Image-Registration-Derived Lung Biomechanics in SPIROMICS.. J Imaging. 8(11)
Burkes RM, Gassett AJ, Ceppe AS, Anderson W, O'Neal WK, Woodruff PG, Krishnan JA, R Barr G, Han MK, Martinez FJ et al..  2018.  Rural Residence and Chronic Obstructive Pulmonary Disease Exacerbations. Analysis of the SPIROMICS Cohort.. Ann Am Thorac Soc. 15(7):808-816.
S
J Wells M, Arenberg DA, Barjaktarevic I, Bhatt SP, Bowler RP, Christenson SA, Couper DJ, Dransfield MT, Han MK, Hoffman EA et al..  2019.  Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy.. Ann Am Thorac Soc. 16(4):439-446.
Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, R Barr G, Comellas AP, Hansel NN, Cooper CB et al..  2019.  Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study.. Sci Rep. 9(1):11367.
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
Putcha N, Puhan MA, M Drummond B, Han MK, Regan EA, Hanania NA, Martinez CH, Foreman M, Bhatt SP, Make B et al..  2014.  A simplified score to quantify comorbidity in COPD.. PLoS One. 9(12):e114438.
Zeidler MR, Martin JL, Kleerup EC, Schneider H, Mitchell MN, Hansel NN, Sundar K, Schotland H, Basner RC, J Wells M et al..  2018.  Sleep disruption as a predictor of quality of life among patients in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS).. Sleep. 41(5)
Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE et al..  2021.  Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.. Respir Res. 22(1):127.
Sieren JP, Newell JD, R Barr G, Bleecker ER, Burnette N, Carretta EE, Couper D, Goldin J, Guo J, Han MK et al..  2016.  SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs.. Am J Respir Crit Care Med. 194(7):794-806.
Bin Cho H, Chae KJu, Jin GYong, Choi J, Lin CLong, Hoffman EA, Wenzel SE, Castro M, Fain SB, Jarjour NN et al..  2019.  Structural and Functional Features on Quantitative Chest Computed Tomography in the Korean Asian versus the White American Healthy Non-Smokers.. Korean J Radiol. 20(7):1236-1245.
Hansel NN, Paulin LM, Amanda G, Roger P, Alexis NE, Fan V, Bleecker E, Bowler RP, Comellas AP, Dransfield MT et al..  2017.  Subpopulations and Intermediate Outcomes in COPD (SPIROMICS) Air Pollution Study Design. BJM Open Respiratory Research. 4(1)
Garudadri S, Woodruff PG, Han MK, Curtis JL, R Barr G, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G et al..  2019.  Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS.. Chest. 155(5):908-917.
U
[Anonymous].  0.  Understanding Age-Related Differences in Quality of Life Between Middle-Aged and Older Adults with COPD.
Putcha N, R Barr G, Han MK, Woodruff PG, Bleecker ER, Kanner RE, Martinez FJ, Smith BM, Tashkin DP, Bowler RP et al..  2016.  Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort.. Thorax. 71:411-420.
V
Bradford E, Jacobson S, Varasteh J, Comellas AP, Woodruff P, O'Neal W, DeMeo DL, Li X, Kim V, Cho M et al..  2017.  The value of blood cytokines and chemokines in assessing COPD.. Respir Res. 18(1):180.
Anderson WH, Ha JWook, Couper DJ, O'Neal WK, R Barr G, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, M Drummond B et al..  2017.  Variability in objective and subjective measures affects baseline values in studies of patients with COPD.. PLoS One. 12(9):e0184606.

Pages